Evidence map›Paper›PMID 28865418›Full record

ArticleIranian biomedical journal2018

ODF4, MAGEA3, and MAGEB4: Potential Biomarkers in Patients with Transitional Cell Carcinoma

Mandana Afsharpad, Mohammad Reza Nowroozi, Mohsen Ayati, Mojtaba Saffari, Saeed Nemati, Elham Mohebbi, Leila Nekoohesh, Kazem Zendehdel, Mohammad Hossein Modarressi

Open access · greenAbstract read
In one paragraph

Article in Iranian biomedical journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mandana AfsharpadCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Reza NowrooziUro Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohsen AyatiUro Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mojtaba SaffariCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Saeed NematiCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Elham MohebbiCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Leila NekooheshDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
Kazem ZendehdelCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Hossein ModarressiCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRMotamed Cancer Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to evaluate the diagnostic value of outer dense fiber 4 (ODF4), melanoma-associated antigen A3 (MAGEA3), and MAGEAB4 mRNAs in transitional cell carcinoma (TCC), using a small amount of cell reverse transcriptase-polymerase chain reaction (RT-PCR) on urinary exfoliated cells. Methods: We recruited a total of 105 suspected TCC patients and 54 sex- and age-matched non-TCC controls. The candidates’ genetic expression patterns were investigated with RT-PCR, while reverse transcription quantitative PCR was applied to quantify and compare each mRNA level between cases and control groups. Results: The sensitivity of ODF4, MAGEA3, and MAGEAB4 RT-PCR was 54.8%, 63%, and 53.4%, whereas the specificity was 73.7%, 86%, and 94.7%, respectively. Combining ODF4, MAGEA3, and MAGEAB4 RT-PCR offered a relatively higher sensitivity (83.6%). Conclusion: RT-PCR with ODF4, MAGEA3, and MAGEAB4 on urinary exfoliated cells could provide clinicians with a promising method to improve TCC diagnosis, especially in the case of gross hematuria and catheterization. The method used here is non-invasive, simple and convenient, and unlike cytology, it does not rely directly on expert professional opinions. These features can be of particular importance to the management of TCC patients in whom regular and lifelong surveillance is required.

Indexed as

Cancer testis antigenClinical markersHuman outer dense fiber of sperm tails 4 proteinTransitional cell carcinoma

Identifiers

PMID28865418
PMCPMC5889501
OpenAlexW2765359891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.